The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Kawasaki Guideline Urges Treatment Intensification for Some Patients

Kawasaki Guideline Urges Treatment Intensification for Some Patients

December 16, 2021 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
MIA Studio / shutterstock.com

MIA Studio / shutterstock.com

A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline follows other recent, jointly published vasculitis guidelines.2-4

You Might Also Like
  • 2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease
  • Gene Expression Signature Useful for Diagnosing Kawasaki Disease
  • Exploring Kawasaki Disease
Explore This Issue
December 2021
Also By This Author
  • ‘Battle for Health Justice’: Dr. Alakija Addresses Global Rheumatology Inequities

Kawasaki Disease

In 1967, Tomisaku Kawasaki, MD, was the first to recognize the syndrome that became known as Kawasaki disease.5 The acute, systemic, medium-vessel vasculitis is found most often in patients younger than 5. The most common form of childhood primary vasculitis globally, it is also the most common cause of acquired heart disease in developed countries.6 Currently, despite best available treatments, a substantial portion of patients still develop coronary artery aneurysms, with an even greater risk in infants younger than 6 months old.6 These can cause serious complications, including cardiac infarction and death.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Guideline Creation Process

As with previous recent ACR guidelines, the guideline development team employed the GRADE methodology (Grading of Recommendations, Assessment, Development and Evaluation) to ensure a systematic approach. The standard PICO format (patient population, intervention, comparison, outcome) was used to develop the specific clinical questions to be evaluated. Ultimately, voting panel members voted on each specific PICO question to produce the final recommendations in the guideline.

Dr. Gorelik

Dr. Gorelik

One core team member was Mark Gorelik, MD, an assistant professor in the Division of Pediatric Rheumatology, Allergy and Immunology at Columbia University, Vagelos College of Physicians and Surgeons, New York. Dr. Gorelik points out that this new ACR guideline on Kawasaki disease is not meant to supplant the existing 2017 guideline from the American Heart Association (AHA).7 Instead, the ACR guideline predominantly focuses on the patients whom rheumatologists are asked to manage most frequently—patients with symptoms of arthritis or macrophage activation syndrome, or patients with particularly severe or refractory disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A pediatric infectious disease specialist, Adriana H. Tremoulet, MD, MAS, professor of pediatrics and the associate director of the Kawasaki Disease Research Center at the University of California, San Diego, also served on the voting panel. Compared with the AHA guideline, she says, the ACR guideline is more treatment focused and less directly centered on cardiovascular issues, and it attempts to fill in questions that have emerged since the earlier guideline was created.

Partly because of the state of the emerging evidence on this topic, reaching consensus was challenging in some areas. “We still just don’t know a lot about the mechanistic or molecular basis of Kawasaki disease, and that also makes it harder to develop the evidence,” says Dr. Gorelik.

Recommendations

Following is a selected discussion of some of the recommendations. For more detail and to see the full context of these recommendations, refer to the full guideline document.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Good Practice Statement: IVIG is the standard-of-care therapy for the initial treatment of Kawasaki disease.

Although much remains unclear about the optimal treatment of Kawasaki disease, we know the administration of IVIG as soon as possible after diagnosis is extremely effective in reducing complications. “We wanted to define this as the central thesis of Kawasaki disease therapy,” Dr. Gorelik says.

Conditional Recommendations: 1) Patients at high risk of IVIG resistance or developing coronary artery aneurysms should receive IVIG with adjunctive glucocorticoids as initial therapy instead of IVIG alone. 2) Such patients should receive IVIG with other non-glucocorticoid immunomodulatory agents over IVIG alone.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Guidelines, Vasculitis Tagged With: Kawasaki disease, VasculitisIssue: December 2021

You Might Also Like:
  • 2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease
  • Gene Expression Signature Useful for Diagnosing Kawasaki Disease
  • Exploring Kawasaki Disease
  • Doctors Detail Kawasaki-Like Disease in Adult COVID-19 Patients

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.